Clinical Trials Logo

Filter by:
NCT ID: NCT03775577 Recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Exercise Intolerance in Heart Failure

Start date: April 1, 2017
Phase:
Study type: Observational

The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle in patients with heart failure with preserved ejection fraction (HFpEF) are associated with debilitating exercise intolerance.

NCT ID: NCT03890575 Recruiting - Malignant Neoplasm Clinical Trials

Airway Segmented Stent Modified With 3D Printing for Malignant Stricture Involving Carina and Distal Bronchi

Start date: April 1, 2017
Phase: N/A
Study type: Interventional

In this study, we used the covered metallic segmented airway stent to treat malignant strictures involving carina and bronchi distal to carina and aimed to determine the feasibility, efficacy and safety of this technique.

NCT ID: NCT03982524 Recruiting - Clinical trials for Somatic Symptom Disorder (DSM-5)

CBT Enriched With Emotion Regulation Training for Multiple Somatoform Symptoms (ENCERT) - A 3-year Follow-up

ENCERT-3YFU
Start date: April 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether 3 years after the end of therapy cognitive-behavioral therapy complemented with strategies from emotion regulation training leads to better improvement in somatic symptoms and comorbid problems in patients with chronic multiple somatoform symptoms than cognitive behavioral therapy alone.

NCT ID: NCT04107584 Recruiting - Hypertension Clinical Trials

Prognostic Value of Plasma Biomarkers Among Patients With Hypertension

BIOMS-HTN
Start date: April 1, 2017
Phase:
Study type: Observational

Hypertension is the most important risk factor for cardiovascular and cerebrovascular diseases,and also a substantial public health problem. The purpose of the study is to investigate the association between plasma biomarkers and adverse outcomes in patients with hypertension.

NCT ID: NCT04169685 Recruiting - Safety Issues Clinical Trials

Dexmedetomidine for Sedation Undergoing Bronchoscopy

Start date: April 1, 2017
Phase:
Study type: Observational

Several sedatives or analgesics can be used to achieve appropriate levels of sedation for endoscopic procedures. Dexmedetomide is notable for providing sedation without respiratory depression. We hypothesized dexmedetomide is more suitable for sedation of bronchoscopy than other sedative drugs.

NCT ID: NCT04342403 Recruiting - Sarcoidosis Clinical Trials

Patient Reported Outcome Instruments in Sarcoidosis

OSAP-PRO
Start date: April 1, 2017
Phase:
Study type: Observational

Evaluate change of quality of life of sarcoiodosis patients over a six months using various quality of life instruments including a monthly smart phone app.

NCT ID: NCT04693962 Recruiting - Acute Kidney Injury Clinical Trials

FGF23 as a Marker of Acute Kidney Injury

Start date: April 1, 2017
Phase:
Study type: Observational

A partial nephrectomy (PN) preserves renal parenchyma with a proper oncology outcome. PN is performed during transitory ischemia to avoid massive bleeding during tumor resection. Nevertheless, the transitory ischemia might cause an acute kidney injury(AKI). AKI diagnose is based on the increase in plasma creatinine concentration and a decrease in urine output. However, both plasma creatinine concentration and diuresis are useful for the diagnose, but not in the detection of the risk patients. Therefore, there is considerable interest to find a biomarkers of kidney injury that allow clinicians to predict the development of AKI. Hence, we propose Fibroblastic Growth Factor-23 (FGF23) as a novel early biomarker to detect patients in risk to develop postoperative AKI after a PN. We will conduct an observational and prospective study in three different groups of patients: PN gropup, patients who underwent PN with a transient and controlled renal ischemia injury using a renal artery clamping; Hemicolectomy (HC) group, patients as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC; and Nephrolithotomy (NL) group, patients who underwent NL, as a control of kidney surgery with physical injury. In each patient, a time curve of plasmatic creatinine, blood urea nitrogen (BUN), and FGF23 were measure. Our study aims to describe the role of FGF23 as an early biomarker of AKI after PN, where patients are exposed to a controlled ischemic injury.

NCT ID: NCT04905004 Recruiting - Clinical trials for Class II Division 1 Malocclusion

Efficiency of Canine Retraction Using Different Reactivation Intervals

Start date: April 1, 2017
Phase: N/A
Study type: Interventional

Canine retraction after 1st premolar extracion into the extraction space is a routine treatment in orthodontics. Orthodontic patients requiring first premolar extraction, canine retraction and maximum anchorage were recruited for this randomized controlled trial. A search of the literature did not indicate the ideal frequency of elastomeric chain reactivation for optimum canine retraction. The study was approved by the ethical committee. The first premolars were extracted. Elastomeric chains were used to retract the canine distally into the 1st premolar space. The optimum reactivation interval was evaluated regarding the efficiency of treatment in terms of rate of canine retraction, canine tipping and rotation, root resorption and pain at the intervals of 2, 4, 6 and 8 weeks. Three dimensional imaging, as well as digital scanning were the methods for data collection.

NCT ID: NCT05322265 Recruiting - Clinical trials for Surgery--Complications

Complication in Laparoscopic Renal and Adrenal Surgery (CLARAS)

CLARAS
Start date: April 1, 2017
Phase:
Study type: Observational

the aim of this study is clarify complication and their resolution in laparoscopic renal and adrenal surgery.

NCT ID: NCT05382585 Recruiting - Oral Cancer Clinical Trials

Newer Therapeutic Targets in Head and Neck Cancers

Start date: April 1, 2017
Phase:
Study type: Observational

Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes: 1. cellular survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA); 2. cell-cycle control (e.g., CDKN2A and CCND1); 3. cellular differentiation (e.g., NOTCH1); and 4. Adhesion and invasion signaling (e.g., FAT1).7 TP53, EGFR, PIK3CA, CDKN2A, CCND1, and MET participate in several common signaling pathways. Alterations of these genes are most frequently seen in alcohol and tobacco-related HNSCC. However their role in prognostication and selection of therapeutics is not known